< Back

April, 2018

Across Stakeholders, Spiriva, Flovent, and Ventolin Continue to Lead Brands in Access

Knowledge Edge Brand Access Marketplace Dynamics | April 2018

Across Stakeholders, Spiriva, Flovent, and Ventolin Continue to Lead Brands in Access

Within each class, stakeholders are increasingly selecting one or two market-leading brands as first line options; overall, biologics remain a later-line therapeutic option, however many providers are more willing to position Xolair earlier in their treatment order.

Across Stakeholders, Spiriva, Flovent, and Ventolin Continue to Lead Brands in Access

Download Complimentary Slide

These and other findings can be found in Health Strategies Group’s recently released research Respiratory Market Access Stakeholder Drug Management Landscape.

Key topics included in this research:
Summary analysis

  • Capabilities assessment by stakeholder on access risks and opportunities
  • Impact analysis for biopharmaceutical companies

Current stakeholder use of general and brand-specific management tactics

  • Preferred brand selection
  • Utilization management
  • Distribution management
  • Alternative payment models, financial incentives, and performance metrics

View the Research Agenda

Visit our Brand Access Marketplace Dynamics webpage to learn more about this research.

Disclaimer

 

Please complete the form to have this document sent to your email.

 

Please complete the form to have this document sent to your email.